Amgen Inc.'s 24 percent increase in income in the third quarter was not enough to counter investors concerns Thursday about a second complete response letter for Prolia (denosumab) and new data suggesting there were higher rates of cancer deaths in chronic kidney disease patients administered the firm's erythropoiesis stimulating agent Aranesp (darbepoetin alfa). (BioWorld Today) Read More
